TG Therapeutics' Q3 earnings missed EPS expectations despite Briumvi's revenue growth. See why TGTX stock is a Buy.

TG Therapeutics, Inc. reported a modest Q3 beat and raised the full-year net sales guidance range for Briumvi by $7.5 million ...

During the third quarter, TG Therapeutics boosted Briumvi's market penetration, driving U.S. net revenue up by over 230% year ...

Tara Bancroft’s rating is based on the promising potential of TG Therapeutics’ Briumvi in the anti-CD20 relapsing multiple sclerosis (RMS) market. Briumvi has shown remarkable efficacy with an ...

Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 millionRaises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 ...

STORY HIGHLIGHTS Fujifilm Diosynth will manufacture Briumvi for TG Therapeutics. Briumvi was approved by the FDA in 2022. Fujifilm's Holly Springs site will be operational next year. Fujifilm ...

Q3 2024 Earnings Call Transcript November 4, 2024 TG Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Michael S. Weiss, the Company’s Chairman and Chief Executive Officer stated, “The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and we are ...

U.S. net revenue from Briumvi grew by more than 230% year over year to $83.3 million. Total revenue for Q3 of $83.9 million surpassed analysts' expectations of $81.7 million. Diluted earnings per ...

Michael S. Weiss, the Company’s Chairman and Chief Executive Officer stated, “The positive feedback and uptake of BRIUMVI in the marketplace continues to outpace our expectations and ...

NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the third quarter of 2024, along with ...